ESR1 and breast carcinoma: The existing breast cancer treatment targets the inhibition of estrogen and the prevention of hormone-receptor binding using ER modulators (tamoxifen), inhibitors (aromatase inhibitors), and ER degrading agents like fulvestrant [5,6].